Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Review

(1909) Views  (455) Full article downloads

Authors: Bianca Devitt, Sue-Anne McLachlan

Published Date April 2008 Volume 2008:4(2) Pages 453 - 458

DOI: http://dx.doi.org/10.2147/TCRM.S1966

Bianca Devitt, Sue-Anne McLachlan

St Vincent’s Hospital, Melbourne, Victoria, Australia

Abstract: Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression. Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer. Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations. It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks. Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring. Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate.

Keywords: ibandronate, oral bisphosphonate, bone metastasis, breast cancer, skeletal complications